Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2017-09-11 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
关于收到药品审批意见通知件的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company (福安药业) regarding receipt of a drug approval opinion notice from a regulatory authority (国家食品药品监督管理总局). It states the drug was not approved and mentions no significant impact on current performance. The document is brief (557 characters) and serves as a regulatory update or announcement rather than a detailed report or financial filing. It does not contain financial data, management changes, or voting results. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about drug approval status.
2017-09-11 Chinese
关于控股股东部分股份质押的公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding the pledge of shares by a controlling shareholder. It details the number of shares pledged, the pledgee, and the proportion of shares pledged relative to total holdings and total company shares. There is no financial report, earnings data, or management discussion. The content fits the description of a Major Shareholding Notification, as it informs about changes in significant share ownership levels or encumbrances on shares by a major shareholder. The document length is short and focused solely on share pledge information, not a full report or announcement of a report publication.
2017-09-05 Chinese
关于变更持续督导独立财务顾问主办人的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the change of the lead independent financial advisor overseeing a continuous supervision related to a company's restructuring project. It mentions the replacement of a project lead due to personnel changes and provides a brief biography of the new lead. There is no financial data, no report attached or referenced as being published, and no detailed financial or operational results. The content is an update on a financing advisory role related to a capital raising and acquisition transaction. This fits best under Capital/Financing Update (CAP) as it relates to ongoing financing advisory and supervision changes in a capital transaction context.
2017-09-03 Chinese
第三届监事会第十四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the 14th meeting of the 3rd Supervisory Board of the company 福安药业 (Fuan Pharmaceutical). It includes approval of the 2017 half-year report and its summary, a special report on the use of raised funds for the half-year, and approval of accounting policy changes. The document is short (1093 characters) and primarily serves as a meeting resolution announcement rather than the full half-year report itself. It does not contain detailed financial statements or substantive financial data but confirms the approval of such reports. Therefore, it is not an Interim/Quarterly Report (IR) but rather a Regulatory Filing (RNS) announcing supervisory board decisions and approvals related to the half-year report and other matters.
2017-08-28 Chinese
2017年半年度报告披露提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (348 characters) indicating that the company's 2017 half-year report will be disclosed on a specified date and website. It does not contain the actual half-year financial report or substantive financial data, but rather informs investors to check the report elsewhere. According to the 'MENU VS MEAL' rule, such a brief notice about report availability is classified as a Report Publication Announcement (RPA).
2017-08-28 Chinese
2017年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2017 年半年度报告全文" which translates to "2017 Semi-Annual Report Full Text". It contains detailed financial data, management discussion and analysis, business overview, risk factors, and other comprehensive information typical of an interim or quarterly report. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. It includes financial figures for the half-year period, discussion of business operations, risks, and R&D activities, all consistent with an Interim / Quarterly Report. Therefore, the document is classified as an Interim / Quarterly Report (IR). H1 2017
2017-08-28 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.